How do common blood thinners behave in a cirrhotic liver? new study aims to find out
NCT ID NCT04874428
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase 1 study is looking at how two common blood thinners, rivaroxaban (Xarelto) and apixaban (Eliquis), are processed in the bodies of people with compensated liver cirrhosis. Twenty-four participants will receive a single dose of one of the drugs, and researchers will track drug levels and blood clotting markers over 12 hours. The goal is to gather safety and dosing information, not to treat the cirrhosis itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Visceral Surgery and Medicine, University Hospital Inselspital, Berne
RECRUITINGBern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rivaroxaban and apixaban (blood thinners)
What this could lead to
If successful, this study could help doctors understand how to safely use these blood thinners in people with liver cirrhosis.
What could go wrong
This is a very small, early-phase study with only 24 participants and single doses, so results may not apply to long-term use or all cirrhosis patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.